三陰性乳腺癌分子分型與個(gè)體化靶向治療現(xiàn)狀
發(fā)布時(shí)間：2018-12-20 07:07
【摘要】：目的三陰性乳腺癌(triple-negative breast caner,TNBC)異質(zhì)性大,惡性程度高,預(yù)后差,對(duì)內(nèi)分泌治療及抗HER2治療均不敏感。本研究總結(jié)TNBC的分子分型及靶向治療的臨床研究進(jìn)展,以明確TNBC靶向治療的研究現(xiàn)狀和前景。方法應(yīng)用PubMed及CNKI數(shù)據(jù)庫(kù)檢索系統(tǒng),以"TNBC、分子分型、和靶向治療"等為關(guān)鍵詞,檢索2011-04-2016-04的相關(guān)文獻(xiàn)。納入標(biāo)準(zhǔn):TNBC的分型與靶向治療。根據(jù)納入標(biāo)準(zhǔn),最后納入分析66篇文獻(xiàn)。結(jié)果根據(jù)基因表達(dá)譜,TNBC可分為多種分子亞型,主要為"基底細(xì)胞樣亞型、間充質(zhì)/間充質(zhì)干細(xì)胞亞型、免疫調(diào)節(jié)亞型、管腔雄激素受體亞型"。TNBC主要的靶向治療方式分為5大類:針對(duì)DNA修復(fù)缺陷的靶向藥物、酪氨酸激酶抑制相關(guān)的靶向藥、PI3K-AKT-mTOR通路抑制劑、免疫檢查點(diǎn)抑制劑和雄激素受體抑制劑。其中PARP抑制劑、鉑類、PD-L1抑制劑、AKT抑制劑的研究均已進(jìn)入Ⅲ期臨床試驗(yàn);酪氨酸酶抑制相關(guān)靶向藥物及PI3K/AKT/mTOR通路抑制劑單藥使用的價(jià)值有限,可能更適宜多藥聯(lián)合或與傳統(tǒng)化療藥物聯(lián)合應(yīng)用;雄激素受體抑制劑的治療價(jià)值尚需進(jìn)一步臨床試驗(yàn)的驗(yàn)證。結(jié)論 TNBC有多種分子亞型,多種靶向治療藥物處于臨床研究階段,其中PARP抑制劑、鉑類、PD-L1抑制劑最具有研究前景。
[Abstract]:Objective: triple negative breast cancer (triple-negative breast caner,TNBC) has high heterogeneity, high malignancy and poor prognosis. It is insensitive to endocrine therapy and anti HER2 therapy. In this study, the molecular classification of TNBC and the clinical research progress of targeted therapy were summarized, in order to clarify the current situation and prospects of TNBC targeted therapy. Methods PubMed and CNKI database retrieval system were used to search the literature of 2011-04-2016-04 with the key words of "TNBC, molecular typing, targeting therapy" and so on. Inclusion criteria: TNBC typing and targeted therapy. According to the inclusion criteria, 66 articles were analyzed. Results according to the gene expression profile, TNBC could be classified into several molecular subtypes, including basal cell-like subtype, mesenchymal stem cell subtype and immunomodulatory subtype. Subtypes of androgen receptor in lumen ". The main targeting therapy for TNBC is divided into five categories: targeted drugs for DNA repair defects, tyrosine kinase inhibition related target drugs, PI3K-AKT-mTOR pathway inhibitors, Immune checkpoint inhibitors and androgen receptor inhibitors. The studies of PARP inhibitors, platinum inhibitors, PD-L1 inhibitors and AKT inhibitors have all entered stage 鈪，
本文編號(hào)：2387625
[Abstract]:Objective: triple negative breast cancer (triple-negative breast caner,TNBC) has high heterogeneity, high malignancy and poor prognosis. It is insensitive to endocrine therapy and anti HER2 therapy. In this study, the molecular classification of TNBC and the clinical research progress of targeted therapy were summarized, in order to clarify the current situation and prospects of TNBC targeted therapy. Methods PubMed and CNKI database retrieval system were used to search the literature of 2011-04-2016-04 with the key words of "TNBC, molecular typing, targeting therapy" and so on. Inclusion criteria: TNBC typing and targeted therapy. According to the inclusion criteria, 66 articles were analyzed. Results according to the gene expression profile, TNBC could be classified into several molecular subtypes, including basal cell-like subtype, mesenchymal stem cell subtype and immunomodulatory subtype. Subtypes of androgen receptor in lumen ". The main targeting therapy for TNBC is divided into five categories: targeted drugs for DNA repair defects, tyrosine kinase inhibition related target drugs, PI3K-AKT-mTOR pathway inhibitors, Immune checkpoint inhibitors and androgen receptor inhibitors. The studies of PARP inhibitors, platinum inhibitors, PD-L1 inhibitors and AKT inhibitors have all entered stage 鈪，
本文編號(hào)：2387625
本文鏈接：http://sikaile.net/yixuelunwen/zlx/2387625.html
最近更新
教材專著
